

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Russell Angus C.</u> (Last) (First) (Middle) 1300 NORTH KELLOGG DRIVE, SUITE D (Street) ANAHEIM CA 92807 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>QUESTCOR PHARMACEUTICALS INC [QCOR]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 06/08/2013	
	4. If Amendment, Date of Original Filed (Month/Day/Year) 06/11/2013	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock ⁽¹⁾	06/08/2013		A		5,114 ⁽²⁾	A	\$0.00	5,114	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (right to purchase) ⁽³⁾	\$36.29	06/08/2013		A		11,252		(4)	06/08/2023	Common Stock	11,252	\$0.00	11,252	D	

Explanation of Responses:

1. Restricted stock award granted under the Questcor Pharmaceuticals, Inc. (the "Company") 2006 Equity Incentive Award Plan.
2. Represents a restricted stock award that will vest in four equal annual installments beginning on 6/8/2014.
3. Non-qualified stock options were granted under the Company's 2006 Equity Incentive Awards Plan.
4. Options vest in equal monthly installments over 48 months from the time of grant.

Remarks:

The transactions in each of Table I and Table II are not new or revised but are being reported again solely for the purposes of gaining access to the EDGAR filing system to correct errors contained in footnotes 2 and 4 of the original Form 4 filed on 6/11/2013 (the "Original Form 4"). Footnote 2 to the Original Form 4 incorrectly stated that the restricted stock award vested over on the earlier to occur of (i) 5/24/2014 or (ii) the Company's 2014 Annual Shareholders' Meeting. The vesting schedule for the restricted stock award has been corrected in footnote 2 below. Footnote 4 to the Original Form 4 incorrectly stated that the options vest in equal monthly installments over one year from the time of grant. The vesting schedule for the options has been corrected in footnote 4 below. Footnotes 1 and 3 from the Original Form 4 have been reprinted below for informational purposes only.

/s/ Angus C. Russell

11/13/2013

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.